Hutchmed (China) Limited Blocklisting Six Monthly Return (2357E)

TIDMHCM

RNS Number : 2357E

Hutchmed (China) Limited

29 June 2023

Blocklisting Six Monthly Return

Hong Kong, Shanghai, & Florham Park, NJ - Thursday, June 29, 2023: HUTCHMED (China) Limited (" HUTCHMED " or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:

 
1.   Name of applicant:            HUTCHMED (China) Limited 
2.   Name of scheme:               (a)  Share Option Scheme conditionally adopted 
                                         by HUTCHMED in 2005 ("2005 HUTCHMED 
                                         Share Option Scheme") 
                                   (b)  Share Option Scheme conditionally adopted 
                                         by HUTCHMED in 2015 ("2015 HUTCHMED 
                                         Share Option Scheme") 
3.   Period of return:             From December 29, 2022 to June 28, 2023 
4.   Balance under scheme          (a)  2005 HUTCHMED Share Option Scheme: 883,300 
      from previous return:              ordinary shares of US$0.1 each 
                                   (b)  2015 HUTCHMED Share Option Scheme: 52,667,578 
                                         ordinary shares of US$0.1 each 
5.   The amount by which           (a)  2005 HUTCHMED Share Option Scheme: Nil 
      the block scheme has 
      been increased, if 
      the scheme has been 
      increased since the 
      date of the last return: 
                                   (b)  2015 HUTCHMED Share Option Scheme: Nil 
6.   Number of securities          (a)  2005 HUTCHMED Share Option Scheme: 449,250 
      issued/allotted under 
      scheme during period: 
                                   (b)  2015 HUTCHMED Share Option Scheme: 936,860 
7.   Balance under scheme          (a)  2005 HUTCHMED Share Option Scheme: 434,050 
      not yet issued/allotted            ordinary shares of US$0.1 each 
      at end of the period: 
                                   (b)  2015 HUTCHMED Share Option Scheme: 51,730,718 
                                         ordinary shares of US$0.1 each 
8.   Number and class of           25,198,880 ordinary shares of US$0.1 each 
      securities originally         admitted on June 17, 2019 (to replace the 
      listed and the date           Company's previous block admission schemes 
      of admission:                 following the Company's share subdivision 
                                    which took effect on May 30, 2019) 
 
 
 
 
9.   Total number of securities    866,161,450 ordinary shares of US$0.1 each 
      in issue at the end 
      of the period: 
Name of contact:                   Weiguo Su 
Address of contact:                Level 18, The Metropolis Tower, 10 Metropolis 
                                    Drive, Hung Hom, Kowloon, Hong Kong 
Telephone number of contact:       +852 2121 8200

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/ immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                    +852 2121 8200 
  Annie Cheng, Vice President                        +1 (973) 306 4490 
 
Media Enquiries 
  Americas - Brad Miles,                             +1 (917) 570 7340 (Mobile) | bmiles@soleburystrat.com 
   Solebury Strategic Communications 
  Europe - Ben Atwell / Alex Shaw,                   +44 20 3727 1030 / +44 7771 913 902 (Mobile) / 
   FTI Consulting                                     +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com 
  Asia - Zhou Yi, Brunswick                          +852 97 83 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley / Daphne Zhang, 
   Panmure Gordon                                    +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLREANKPAESDEEA

(END) Dow Jones Newswires

June 29, 2023 04:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024